Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

31 July 2021: Clinical Research

Clinical Benefit of Therapeutic Drug Monitoring in Colorectal Cancer Patients Who Received Fluorouracil-Based Chemotherapy

Xingqin Zhou 1BCE , Yazhou Chang 2BD , Jing Qian 1BF , Chaoyan Shen 1DEF , Jie Han 1EF , Hongyu Zhao 1DF , Renan Chang 3AG*

DOI: 10.12659/MSM.929474

Med Sci Monit 2021; 27:e929474

Table 2 Comparison of patient between the Study Group and the Historical Group.

VariableHistorical Group (n=153)Study Group (n=54)P value
Sex, n (%)0.307
 Male86 (56.2)26 (48.1)
 Female67 (43.8)28 (51.9)
Age (years)0.423
Weight (kg)0.204
Height (cm)0.363
Baseline BSA (m)0.427
Pretreatment ECOG status0.624
Starting infusional 5-FU dose (mg/m)0.125
Protocol of chemotherapy, n0.835
 FOLFOX439 (4)14
 mFOLFOX668 ()26
 FOLFIRI46 ()14
Treatment cycles0.999
Adverse events*
No toxicity or mild toxicity262259
Severe toxicity18530
Chemotherapy response0.032*
SD – standard deviation; FOLFOX – oxaliplatin, folinate, 5-FU; FOLFIRI – irinotecan, folinate, 5-FU.

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750